NAII
Natural Alternatives International, Inc.3.1900
-0.0100-0.31%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
19.70MP/E (TTM)
-Basic EPS (TTM)
-2.00Dividend Yield
0%Recent Filings
8-K
CEO salary cut, Swiss role added
Natural Alternatives International slashed CEO Mark LeDoux's U.S. base salary to $255,000 from $475,000 effective May 1, 2026, while adding a CHF 170,000 role as Managing Director of its Swiss subsidiary. Total pay stays roughly flat despite currency swings. LeDoux commits half his time to Switzerland. Boosts Swiss ops for global revenue push.
10-Q
Q2 FY2026 results
NAI posted Q2 FY2026 net sales of $34.8M, up 2% y/y, with gross profit jumping 49% to $2.5M (7.2% margin from 4.9%) on better factory utilization and product mix in private-label contract manufacturing ($32.8M, +2% y/y). YTD sales rose 8% to $72.5M, gross profit soared 75% to $6.9M (9.5% margin), yet operating loss narrowed to $1.6M from $4.6M while net loss hit $2.8M, widened by $0.5M foreign exchange losses and taxes versus prior benefit. Cash drained to $3.8M amid $10.4M operating outflow and $2.0M capex; free cash flow not disclosed in the 10-Q. Line of credit drew to $5.8M of $10M capacity atop $8.8M term loan, with ongoing covenant waivers but replacement lender talks. Customer concentration lingers.
8-K
Covenant waivers secured
Natural Alternatives International breached its Wells Fargo credit agreement covenants for Q1 fiscal 2026 ended September 30, 2025, exceeding the $250,000 net loss limit and missing the 1.0 fixed charge coverage ratio. Wells Fargo waived these defaults via a December 12, 2025 agreement, effective December 17, keeping the $10M revolving line (maturing 2026) and $10M term note intact. Defaults waived. Lenders hold firm collateral.
8-K
Stockholders approve director, plan
Natural Alternatives International stockholders approved Alan G. Dunn as Class II director, the First Amendment to the 2020 Omnibus Equity Incentive Plan, ratification of Haskell & White LLP as auditors for fiscal 2026, and exec compensation at the December 5, 2025 annual meeting. They favored three-year frequency for say-on-pay votes. Governance aligned with majority support.
10-Q
Q1 FY2026 results
NAI posted Q1 FY2026 net sales of $37.7M, up 14% y/y from $33.2M, with private-label contract manufacturing surging 18% to $36.1M while patent licensing dipped 34% to $1.7M. Gross profit leaped to $4.4M (11.7% margin) from $2.3M (6.8%), fueling operating income of $0.3M versus a $1.8M loss; yet foreign exchange losses and interest flipped it to a slim $0.3M net loss, down 85% y/y, versus $2.0M prior. Cash fell to $7.7M amid $4.0M operating outflow, $2.5M line of credit draw (on $10M facility), and $8.9M term debt; covenant breaches persist, with lender talks underway. Private-label volumes lifted margins. Customer concentration risks loom large.
IPO
Website
Employees
Sector
Industry
ABVE
Above Food Ingredients Inc.
1.83+0.07
AIXN
AIXIN LIFE INTERNATIONAL INC
0.48+0.32
BFNH
BioForce Nanosciences Holdings,
0.60+0.07
CFOO
CHINA FOODS HOLDINGS LTD
0.66+0.00
HAIN
The Hain Celestial Group, Inc.
1.11-0.06
IMG
CIMG Inc.
1.17-0.55
INBP
Integrated BioPharma, Inc.
0.31+0.00
LIMX
Limitless X Holdings Inc.
1.40+0.00
NATR
Nature's Sunshine Products, Inc
22.38-0.85
USNA
USANA Health Sciences, Inc.
20.33+0.01